Anticancer research
-
Anticancer research · Mar 2009
Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Pancreatic cancer is one of the most fatal human cancers, with a 5-year survival rate of <5% . Although new chemotherapies have been used for pancreatic cancer, the outcome is still poor. Here, we retrospectively analyzed the outcome of immunotherapy in pancreatic cancer patients and revealed the potential of immunotherapy in advanced pancreatic cancer treatment. ⋯ Our results suggest that immunotherapy utilizing DC vaccination may prolong the survival of refractory pancreatic cancer patients.